ArticleJournal of pediatrics. Clinical practice2026
Association of Polysubstance Exposure and Neonatal Weight Loss Among Infants Exposed to Opioids.
Article in Journal of pediatrics. Clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize the weight trajectories of infants exposed to opioids and evaluate the association between different exposures and risk of excessive neonatal weight loss. Study design: Using mother-baby linked electronic health records, vital records, and claims data, we identified a retrospective cohort of infants exposed to opioids born at a large, academic medical center (2010-2021). We characterized prenatal substance exposures 90 to 2 days before delivery, including medications for opioid use disorder (MOUD), non-MOUD opioids, selective serotonin reuptake inhibitors, benzodiazepines, gabapentin, cigarette smoking, and toxicology evidence of opioids and nonopioid exposures (eg, barbiturates, cannabinoids, amphetamines, cocaine). We parameterized neonatal weight loss as the maximum percentage decrease from birth weight in the first 14 days of life during birth hospitalization. We used multivariable linear regression to compare the association between prenatal exposures and maximum percentage weight loss. Results: Among 868 maternal-infant dyads exposed to opioids that were identified, 622 (71.7%) had prenatal exposure to at least 1 additional substance. Infants with additional prenatal exposures had a greater median weight loss and a later nadir in weight loss compared with those without additional exposures ( Conclusions: Exposure to MOUD and nonopioid exposures were associated with greater weight loss among infants exposed to opioids during the first 14 days of life. These findings inform the clinical management of infants exposed to opioids to mitigate weight loss during the neonatal hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.